The Effect of Simvastatin Therapy on the Expression of Procoagulant and Inflammatory Markers in Heart Failure
Status:
Completed
Trial end date:
2008-07-01
Target enrollment:
Participant gender:
Summary
Our proposed research will examine whether treatment with simvastatin alters expression and
activity of monocyte TF, whether polymorphisms in the TF gene alter the therapeutic effect
and what effect treatment has on inflammatory markers in heart failure. The results of this
study may assist in tailoring statin therapy to specific characteristics, such as
inflammatory state, of heart failure patients. If treatment with simvastatin significantly
lowers TF expression, this may reduce the risk of thromboembolic events in patients with
heart failure, thus reducing mortality and morbidity. If the treatment effect varies based on
the TF genotype, this may define an identifiable population in whom statin therapy may be
more beneficial than the population as a whole.